beta(3)-Adrenoceptors (beta(3)-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium. They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues. The aim of this review is to highlight the functional role of beta(3)-ARs as well as to discuss their potential for drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phrs.2009.01.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Constitutively active receptor ADGRA3 signaling induces adipose thermogenesis.
Elife
December 2024
Shenzhen Key Laboratory of Systems Medicine for inflammatory diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.
The induction of adipose thermogenesis plays a critical role in maintaining body temperature and improving metabolic homeostasis to combat obesity. β3-adrenoceptor (β3-AR) is widely recognized as a canonical β-adrenergic G-protein-coupled receptor (GPCR) that plays a crucial role in mediating adipose thermogenesis in mice. Nonetheless, the limited expression of β3-AR in human adipocytes restricts its clinical application.
View Article and Find Full Text PDFSafety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey.
Low Urin Tract Symptoms
November 2024
Pharmacovigilance Department, Kyorin Pharmaceutical Co. Ltd., Tokyo, Japan.
Article Synopsis
- The study aimed to assess the safety and effectiveness of vibegron, a drug for treating overactive bladder (OAB), in Japanese patients through a real-world clinical trial over four years.
- Out of 1848 patients, 154 adverse drug reactions (ADRs) were reported, with common side effects including increased urine volume, constipation, and urinary retention, particularly affecting older male patients.
- The drug demonstrated an effectiveness rate of 88.8%, with significant improvements in OAB symptoms observed across all patient groups, making vibegron a valuable option for OAB treatment.
β3 adrenergic receptor activation alleviated PM-induced hepatic lipid deposition in mice.
Sci Total Environ
October 2023
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China; Zhejiang International Science and Technology Cooperation Base of Air Pollution and Health, Hangzhou, China. Electronic address:
Increasing energy expenditure through activation of hepatocytes is a potential approach to treat fine particulate matter (PM) induced metabolic-associated fatty liver disease (MAFLD). Beta-3 adrenergic receptor (β3-AR) agonists could stimulate brown adipose tissue (BAT) energy expenditure, but it has never been investigated in MAFLD. The objective of this study is to explore the therapeutic effects of administering CL-316,243, a selective agonist of β3-AR, on hepatic lipid metabolism disturbances induced by PM.
View Article and Find Full Text PDFRisk of dementia associated with the use of anticholinergic medications: a review of recent literature.
Curr Opin Urol
November 2024
Urology Institute, University Hospitals Cleveland Medical Center.
Purpose Of Review: While there is an established association between the use of anticholinergic medications and its effects on cognition, the extent of this impact remains unclear. We outline recent studies addressing this topic.
Recent Findings: We describe a series of recent articles discussing the risk of dementia associated with anticholinergic medication use in general, with further focus on the risk of overactive bladder (OAB) anticholinergic use, detailing short & long-term use effects, risk variation based on age and gender, and reporting alternative treatment options.
The Effects of Vibegron Add-on Therapy on Alpha 1-Blocker Therapy for Sexual Function and Overactive Bladder Symptoms in Benign Prostatic Hyperplasia: A Prospective, Open-Label Study.
J Clin Med
July 2024
Department of Urology, Teikyo University School of Medicine, Tokyo 173-8606, Japan.
: The effect of combining an α-adrenergic receptor blocker (α-blocker) and the β3-adrenoceptor agonist vibegron for treating persistent overactive bladder (OAB) symptoms associated with benign prostatic hyperplasia (BPH) on sexual function remains uncertain. Therefore, we aimed to evaluate the effects of vibegron as an add-on to α-blocker therapy on both OAB and sexual function. : Forty-three patients with BPH in whom OAB symptoms were inadequately controlled by α-blocker treatment were included in this prospective open-label study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!